Efficacy and Safety of Lactobacillus plantarum DSM 9843 (LP299V) in the Prevention of Antibiotic‐Associated Gastrointestinal Symptoms in Children—Randomized, Double‐Blind, Placebo‐Controlled Study
- 2017-07
- The Journal of Pediatrics 186
- A. Olek
- M. Woynarowski
- I. L. Ahrén
- J. Kierkuś
- P. Socha
- N. Larsson
- G. Önning
- PubMed: 28438377
- DOI: 10.1016/j.jpeds.2017.03.047
Abstract
Objectives: To determine if Lactobacillus plantarum DSM9843 (LP299V) reduces the frequency of antibiotic-associated loose/watery stools and gastrointestinal symptoms, and can be administered safely to children who are prescribed antibiotics.
Study design: We performed a prospective, double-blind, randomized, placebo-controlled, multicenter, parallel-group study in children receiving outpatient antibiotic therapy in primary healthcare settings. The children were given LP299V/placebo during the antibiotic therapy and for 1 week after the end of treatment. The primary outcome measure was the incidence of at least 1 loose/watery stool (type 6 or 7 according to the Bristol Stool Form Scale). Gastrointestinal symptoms (abdominal pain, abdominal distention, vomiting, and flatulence) were followed up until 1 week after the last intake of the study product.
Results: A total of 438 children (male: 235, female: 203) aged 1-11 years (mean ± SD: 5.2 ± 2.7) were randomized to receive LP299V (N = 218) or placebo (N = 220). The incidence of loose/watery stools in the 2 study groups (LP299V and placebo) was similar, 39% vs 44.5% respectively (P = .26) as was the mean number of loose/watery stools (3.9 ± 3.5 vs 4.7 ± 6.3; P = .9). Antibiotic-associated diarrhea (defined as ≥3 loose/watery stools/24 hours starting from 2 hours after initiation of antibiotic treatment until the end of the study) occurred in 2.8% of the subjects receiving LP299V compared with 4.1% in the placebo arm (P = .4). The number of children with abdominal symptoms did not differ between the groups.
Conclusions: No beneficial effect of LP299V compared with placebo was observed for the incidence of loose/watery stools, mean number of loose/watery stools, or the incidence of abdominal symptoms. LP299V had a satisfactory safety profile.
Trial registration: ClinicalTrials.gov: NCT01940913.
Keywords: diarrhea; probiotics.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus plantarum DSM 6595 | Increased Abdominal Symptoms in Children Taking Antibiotics | Neutral | Small |
Lactobacillus plantarum DSM 6595 | Increased Frequency of Loose or Watery Stools | Neutral | Small |
Lactobacillus plantarum DSM 6595 | Reduced Antibiotic-Associated Diarrhea in Children | Neutral | Small |
Lactobacillus plantarum DSM 6596 | Increased Incidence of Abdominal Symptoms | Neutral | Small |
Lactobacillus plantarum DSM 6596 | Reduced Incidence of Loose Stools | Neutral | Small |
Lactobacillus plantarum DSM 6596 | Reduced Stool Volume | Neutral | Small |
Lactobacillus plantarum LP-01 | Reduced Abdominal Symptoms | Neutral | Small |
Lactobacillus plantarum LP-01 | Reduced Antibiotic-Associated Diarrhea | Neutral | Small |
Lactobacillus plantarum LP-01 | Reduced Incidence of Loose Stools | Neutral | Small |
Lactobacillus plantarum LP-01 | Reduced Stool Volume | Neutral | Small |
Lactobacillus plantarum Lp-115 | Improved Safety Profile | Neutral | Moderate |
Lactobacillus plantarum Lp-115 | Reduced Abdominal Symptoms | Neutral | Small |
Lactobacillus plantarum Lp-115 | Reduced Antibiotic-Associated Diarrhea | Neutral | Small |
Lactobacillus plantarum Lp-115 | Reduced Incidence of Loose Stools | Neutral | Small |
Lactobacillus plantarum Lp-115 | Reduced Stool Volume | Neutral | Small |
Lactobacillus plantarum LP09 | Increased Frequency of Loose or Watery Stools | Neutral | Small |
Lactobacillus plantarum LP09 | Reduced Abdominal Symptoms | Neutral | Small |
Lactobacillus plantarum LP09 | Reduced Antibiotic-Associated Diarrhea | Neutral | Small |